Market Place
Sourcing Support
TherapeuticsMD Announces Q3 2024 Financial Results
12 Nov 2024 //
BUSINESSWIRE
TherapeuticsMD Announces Second Quarter 2024 Financial Results
12 Aug 2024 //
BUSINESSWIRE
TherapeuticsMD Announces First Quarter 2024 Financial Results
10 May 2024 //
BUSINESSWIRE
TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
03 Jan 2023 //
BUSINESSWIRE
TherapeuticsMD Announces Second Quarter 2022 Financial Results
15 Aug 2022 //
BUSINESSWIRE
TherapeuticsMD to Report Second Quarter 2022 Financial Results
08 Aug 2022 //
BUSINESS WIRE
TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital
01 Aug 2022 //
BUSINESSWIRE
Private equity buyout of TherapeuticsMD unravels as shareholders balk
14 Jul 2022 //
BIOPHARMADIVE
TherapeuticsMD risks bankruptcy as EW Healthcare extends tender offer
06 Jul 2022 //
SEEKING ALPHA
TherapeuticsMD Appoints Mark Glickman as Chief Business Officer
15 Oct 2021 //
BUSINESSWIRE
TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA®
23 Aug 2021 //
BUSINESSWIRE
TherapeuticsMD Announces Appointment of Hugh O’Dowd as President
09 Aug 2021 //
BUSINESSWIRE
TherapeuticsMD to present ANNOVERA® Data at the ACOG 2021
03 May 2021 //
BUSINESSWIRE
TherapeuticsMD Provides Update on Third Quarter Progress
25 Sep 2020 //
BUSINESSWIRE
Knight and TherapeuticsMD Announce Health Canada Approval of BIJUVA®
21 Sep 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.